JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism
JCF alleviates MAFLD by modulating the gut-liver axis and lipid metabolism. Its effects involve improving gut barrier function, regulating microbiota, and targeting the pparγ-cd36 axis. Active compounds like betulinic acid support its therapeutic potential. JCF shows promise as a novel treatment for MAFLD, with further clinical studies needed.
Authors
- Ruijia Liu (ORCID: https://orcid.org/0000-0002-2928-8066)
- Hening Chen (ORCID: https://orcid.org/0000-0001-8539-6857)
- Shihao Zheng (ORCID: https://orcid.org/0000-0002-8694-893X)
- Xiaobin Zao (ORCID: https://orcid.org/0000-0002-7533-1301)
- Wei Wang (ORCID: https://orcid.org/0000-0002-8671-1959)
- Wenying Qi (ORCID: https://orcid.org/0009-0002-4328-7008)
- Yongan Ye (ORCID: https://orcid.org/0000-0001-9765-4665)
- Xu Cao (ORCID: https://orcid.org/0000-0002-9566-6440)
- Yue Chen (ORCID: https://orcid.org/0009-0004-5110-6400)
- Xiaoke Li (ORCID: https://orcid.org/0000-0002-1775-3063)
- Ningyi Zhang (ORCID: https://orcid.org/0009-0001-6135-8140)
- Size Li (ORCID: https://orcid.org/0009-0008-3809-0183)
- Qiyao Liu (ORCID: https://orcid.org/0000-0002-7657-6167)
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1016/j.phymed.2025.156559
- Citations
- 13
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 17.60